نتائج البحث - "Peter T.C. Ho"

1

دورية أكاديمية

A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects

المؤلفون: Azra Hussaini, Rajat Mukherjee, Dina M. Berdieva, Christen Glogowski, Richard Mountfield, Peter T.C. Ho

المصدر: Clinical and Translational Science, Vol 13, Iss 2, Pp 337-344 (2020)

مصطلحات موضوعية: Therapeutics. Pharmacology, RM1-950, Public aspects of medicine, RA1-1270

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1752-8054; https://doaj.org/toc/1752-8062

URL الوصول: https://doaj.org/article/b36ecae080e7425db420993303572fc3

View record at Wiley

Find this article in full text from ProQuest

Full Text Finder

2

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children

المصدر: European Journal of Cancer. 139:135-148

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c517dea500b05206723e5227a0df2155
https://doi.org/10.1016/j.ejca.2020.08.014

View record from ScienceDirect

Full Text via ClinicalKey

3

A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects

المؤلفون: Richard Mountfield, Dina M. Berdieva, Rajat Mukherjee, Peter T.C. Ho, Azra Hussaini, Christen Glogowski

المصدر: Clinical and Translational Science, Vol 13, Iss 2, Pp 337-344 (2020)
Clinical and Translational Science

مصطلحات موضوعية: Adult, CD4-Positive T-Lymphocytes, Male, STAT3 Transcription Factor, Adolescent, Injections, Subcutaneous, Population, Cmax, Biological Availability, Pharmacology, Placebo, Drug Administration Schedule, Article, General Biochemistry, Genetics and Molecular Biology, Young Adult, Double-Blind Method, Pharmacokinetics, Immune Tolerance, Humans, Medicine, Phosphorylation, General Pharmacology, Toxicology and Pharmaceutics, Infusions, Intravenous, education, education.field_of_study, Dose-Response Relationship, Drug, business.industry, Interleukins, Research, lcsh:Public aspects of medicine, General Neuroscience, lcsh:RM1-950, Antibodies, Monoclonal, lcsh:RA1-1270, Articles, General Medicine, Middle Aged, Healthy Volunteers, CD4 Lymphocyte Count, Dose–response relationship, Tolerance induction, lcsh:Therapeutics. Pharmacology, Tolerability, Area Under Curve, Pharmacodynamics, Female, business, Follow-Up Studies, Half-Life

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc500739dd2b26a694dc69b112167e87
https://doi.org/10.1111/cts.12715

View record at Wiley

Find this article in full text from ProQuest

4

BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results

المؤلفون: Vivek Subbiah, Shelley Knight, Byoung Chul Cho, Peter T.C. Ho, Loic Verlingue, Patrick Schöffski, Christophe Massard, Herbert H. Loong, Karen Andreas, Alicia Clawson, Mitchell Keegan, Anita Scheuber, Laura Medina Rodriguez, Craig T. Basson, Antoine Italiano, Jin-Yuan Shih

المصدر: Journal of Clinical Oncology. 39:3008-3008

مصطلحات موضوعية: Cancer Research, Oncology, business.industry, Disease progression, Mutant, Cancer research, Medicine, Rearranged during transfection, RET Fusion, Kinase activity, business, Gene

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b517afe0997b0b261f9b511e25ce0a52
https://doi.org/10.1200/jco.2021.39.15_suppl.3008

5

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

المؤلفون: Igor Feldman, Elayne Chan-Penebre, Alexandra R. Grassian, Kelli A. Armstrong, Kristy Kuplast-Barr, John Campbell, Sarah K. Knutson, Heike Keilhack, Maria Roche, Peter T.C. Ho, Scott Ribich, J. Joshua Smith, Robert A. Copeland, Richard Chesworth, Allison Drew

المصدر: Molecular Cancer Therapeutics. 16:850-860

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::747f40bb502acb9ed4d112bf0f390043
https://doi.org/10.1158/1535-7163.mct-16-0678

6

24 Phase 1 study in healthy volunteers to assess PK, PD safety & tolerability of BOS161721, an extended half-life anti-IL21 monoclonal antibody

المؤلفون: Peter T.C. Ho, Xavier Valencia, Christen Glogowski, Richard Mountfield, Azra Hussaini

المصدر: Abstracts.

مصطلحات موضوعية: biology, business.industry, Pharmacology, Placebo, Pharmacokinetics, Tolerability, Pharmacodynamics, biology.protein, Medicine, Dosing, Antibody, Adverse effect, business, PK/PD models

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::8ae7a3f2dc719ee8021cce9470099c7e
https://doi.org/10.1136/lupus-2019-lsm.24

7

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

المصدر: The Lancet. Oncology. 19(5)

مصطلحات موضوعية: 0301 basic medicine, Male, medicine.medical_specialty, Lymphoma, B-Cell, Time Factors, Maximum Tolerated Dose, Nausea, Pyridones, Morpholines, Population, Antineoplastic Agents, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Refractory, Refractory B-Cell Non-Hodgkin Lymphoma, Internal medicine, medicine, Clinical endpoint, Humans, Enhancer of Zeste Homolog 2 Protein, Enzyme Inhibitors, Adverse effect, education, Aged, education.field_of_study, Dose-Response Relationship, Drug, business.industry, Biphenyl Compounds, Middle Aged, medicine.disease, Lymphoma, 030104 developmental biology, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Pharmacodynamics, Benzamides, Female, France, medicine.symptom, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1d06c96b0b6639ea8bac83480b451e1
https://pubmed.ncbi.nlm.nih.gov/29650364

View record from ScienceDirect

Find this article in full text from ProQuest

Full Text via ClinicalKey

8

Abstract 2199: BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development

المؤلفون: Keith M. Wilcoxen, Mitchell Keegan, Peter T.C. Ho

المصدر: Cancer Research. 79:2199-2199

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4265f21ea7bb679ef4be95455e13935c
https://doi.org/10.1158/1538-7445.am2019-2199

9

A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer

المؤلفون: Christiane Jungels, Patrick Schöffski, Philippe Aftimos, Christophe Massard, Antoine Italiano, Peter T.C. Ho, Karen Andreas, Mitchell Keegan

المصدر: Journal of Clinical Oncology. 37:TPS3162-TPS3162

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a81e134ba3ef710eb15e85c357c09d14
https://doi.org/10.1200/jco.2019.37.15_suppl.tps3162

10

Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

المصدر: Clinical Lymphoma Myeloma and Leukemia. 17:S380-S381

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Tazemetostat, business.industry, EZH2, Hematology, Multicenter study, Refractory B-Cell Non-Hodgkin Lymphoma, Internal medicine, Medicine, In patient, business, Interim report

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::805bfdab3813b2053e21fd3e691246b5
https://doi.org/10.1016/j.clml.2017.07.227

View record from ScienceDirect

Full Text via ClinicalKey

تنقيح النتائج